Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions

Genetic counselling and genetic testing in hypertrophic cardiomyopathy (HCM) represent an integral part of the diagnostic algorithm to confirm the diagnosis, distinguish it from phenocopies, and suggest tailored therapeutic intervention strategies. Additionally, they enable cascade genetic testing in the family. With the implementation of Next Generation Sequencing technologies (NGS), the interpretation of genetic data has become more complex. In this regard, cardiologists play a central role, aiding geneticists to correctly evaluate the pathogenicity of the identified genetic alterations. In the ideal setting, geneticists and cardiologists must work side by side to diagnose HCM as well as convey the correct information to patients in response to their many questions and concerns. After a brief overview of the role of genetics in the diagnosis of HCM, we present and discuss the frequently asked questions by HCM patients throughout our 20-year genetic counselling experience. Appropriate communication between the team and the families is key to the goal of delivering the full potential of genetic testing to our patients.

[1]  G. Limongelli,et al.  Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. , 2022, Archives of cardiovascular diseases.

[2]  J. Kovacic,et al.  Athletic Activity for Patients With Hypertrophic Cardiomyopathy and Other Inherited Cardiovascular Diseases: JACC Focus Seminar 3/4. , 2022, Journal of the American College of Cardiology.

[3]  J. Natoli,et al.  The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—A systematic review and meta‐analysis , 2022, Journal of genetic counseling.

[4]  F. Girolami,et al.  [Clinical pathway on pediatric cardiomyopathies: a genetic testing strategy proposed by the Italian Society of Pediatric Cardiology]. , 2022, Giornale italiano di cardiologia.

[5]  E. Ashley,et al.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  E. Behr,et al.  Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. , 2022, European heart journal.

[7]  S. Day,et al.  Translation of New and Emerging Therapies for Genetic Cardiomyopathies , 2021, JACC. Basic to translational science.

[8]  OUP accepted manuscript , 2021, European Heart Journal.

[9]  F. Girolami,et al.  [Clinical pathway for cardiomyopathies: a genetic testing strategy proposed by ANMCO in Tuscany]. , 2020, Giornale italiano di cardiologia.

[10]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[11]  S. Solomon,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[12]  C. Semsarian,et al.  Variable Penetrance in Hypertrophic Cardiomyopathy: In Search of the Holy Grail. , 2020, Journal of the American College of Cardiology.

[13]  Robert W. Williams,et al.  Identifying modifier genes for hypertrophic cardiomyopathy. , 2020, Journal of molecular and cellular cardiology.

[14]  C. Semsarian,et al.  Screening children at risk for hypertrophic cardiomyopathy: balancing benefits and harms. , 2019, European heart journal.

[15]  S. Ommen,et al.  To Screen or Not to Screen, That Is the Question. , 2019, Circulation.

[16]  B. Maron,et al.  Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. , 2019, Circulation.

[17]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[18]  C. Seidman,et al.  Genetic Testing and Counseling for Hypertrophic Cardiomyopathy. , 2019, Cardiology clinics.

[19]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[20]  F. Salvi,et al.  Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure , 2018, European journal of heart failure.

[21]  D. Judge,et al.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[22]  S. Cook,et al.  Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center , 2018, Genetics in Medicine.

[23]  E. Arbustini,et al.  Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications , 2017, Journal of cardiovascular medicine.

[24]  R. Ardehali,et al.  Cardiac manifestations of PRKAG2 mutation , 2018, BMC Medical Genetics.

[25]  C. Wanner,et al.  Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. , 2017, Molecular genetics and metabolism.

[26]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[27]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[28]  Y. Pinto,et al.  Genetic advances in sarcomeric cardiomyopathies: state of the art , 2015, Cardiovascular research.

[29]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[30]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[31]  B. Maron,et al.  Hypertrophic cardiomyopathy , 2013, The Lancet.

[32]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[33]  Despina Sanoudou,et al.  Molecular genetics made simple , 2012, Global cardiology science & practice.

[34]  J. Seidman,et al.  Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. , 2011, Circulation research.

[35]  Michael J Ackerman,et al.  Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.

[36]  C. Skrzynia,et al.  Genetic Counseling and Testing for Hypertrophic Cardiomyopathy: An Adult Perspective , 2009, Journal of cardiovascular translational research.

[37]  Massimo Baldi,et al.  [A new type of "tracing" for cardiologists?]. , 2009, Giornale italiano di cardiologia.

[38]  J. Seidman,et al.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. , 2009, JAMA.

[39]  Rachael,et al.  Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.

[40]  F. Girolami,et al.  Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. , 2003, The American journal of cardiology.

[41]  M. Komajda,et al.  Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience , 2002, Journal of medical genetics.

[42]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[43]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[44]  C. Lambrew,et al.  Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.